Coherus Oncology (CHRS) Revenue (2013 - 2026)

Coherus Oncology has disclosed Revenue across 13 years of filings, most recently posting $14.3 million for Q2 2026.

• In Q2 2026, Revenue rose 39.53% year-over-year to $14.3 million; the TTM figure through Jun 2026 stood at $50.9 million (up 61.0% YoY), while the FY2025 annual figure was $42.2 million, up 59.81% from the prior year.
• Revenue came in at $14.3 million for Q2 2026 at Coherus Oncology, up from $12.3 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $91.5 million in Q4 2023 to a low of $2.3 million in Q1 2024.
• Average Revenue over 5 years is $31.3 million, with a median of $13.5 million recorded in 2025.
• Year-over-year, Revenue slumped 92.88% in 2024 and jumped 229.25% in 2025.
• Over 5 years, Revenue stood at $45.4 million in 2022, then surged by 101.81% to $91.5 million in 2023, then tumbled by 91.55% to $7.7 million in 2024, then soared by 64.85% to $12.7 million in 2025, then advanced by 12.23% to $14.3 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $14.3 million in Q2 2026, $12.3 million in Q1 2026, and $12.7 million in Q4 2025.